Advancing Combination Therapies to Change the Treatment Paradigm in IBD
Time: 4:30 pm
day: Day One
Details:
- Scientific and clinical rationale for targeting ɑ4β7, TL1A, and IL-23 pathways in IBD therapy
- Nonclinical data demonstrating enhanced efficacy and extended half-life of biologics for combination treatments
- Addressing the natural questions around patient selection for combination therapies: early hypotheses and future directions
